Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 109, Issue 2, Pages 241-250Publisher
SPRINGER
DOI: 10.1007/s10549-007-9640-6
Keywords
estrogen receptor beta; breast cancer; tamoxifen; fulvestrant; raloxifene; antiestrogens
Categories
Funding
- NCI NIH HHS [R01 CA 80210] Funding Source: Medline
Ask authors/readers for more resources
Clinical evidence indicates that higher levels of estrogen receptor beta (ER beta) predicts improved disease-free and overall survival in patients treated with adjuvant tamoxifen therapy. To better understand the mechanisms in which ERb can modulate breast cancer therapies, we introduced ERb under an inducible promoter into MCF-7 breast cancer cells. In these cells, induction of ERb expression led to a shift in the potency and an increase in the efficacy of tamoxifen to inhibit proliferation. A similar effect on breast cancer cells was observed for two other antiestrogens, raloxifene, and fulvestrant. Induced expression of ERb did not enhance the antiproliferative effects of small molecule inhibitors that target the epidermal growth factor receptor, insulin growth factor receptor-1 and histone deacetylase, indicating ERb specifically cooperates with antiestrogens. The combination of ERb expression, which arrests cells in G2, and tamoxifen, which arrests cells in G1, led to a potent blockade of the cell cycle. ERb also increased tamoxifen-induced cell death and cooperated with tamoxifen to induce expression of the proapoptotic gene bik. In summary, our data indicates that ERb increases the efficacy of antiestrogens by effects on apoptosis and on cell cycling and, together with clinical observations, suggests ERb could be a valuable prognostic marker and potential therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available